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Introduction 
 
Anti-retroviral therapy (ART) reduces morbidity and increases life expectancy among people living with 
HIV, but some patients still experience symptoms, including sensory neuropathy (HIV-SN). 
Neuropathies resulting from HIV infection itself and toxic side-effects of ART have similar presentations, 
and include neuropathic pain, tingling and numbness.1-3 Neuropathy was the dose limiting toxicity in 
early trials of some of the nucleoside analogue reverse transcriptase inhibitors (NRTIs) used to treat 
HIV: zalcitabine (ddC), didanosine (ddI) and stavudine (d4T). Hence rates of HIV-SN rose when these 
drugs entered clinical use, and exposure to ART emerged as a neuropathy risk factor. Stavudine was 
used in first line ART until well into the 21st century, especially in resource limited countries. The 
prevalence of HIV-SN in patients receiving stavudine at Cipto Mangunkusumo Hospital, Jakarta, 
Indonesia in 2006 was 34%. In this cohort, the observed associations with HIV-SN among stavudine 
treated patients were increasing age and height.4,5   In black South African HIV patients exposed to 
stavudine, identical assessment methods revealed an HIV-SN prevalence of 57%.6 Again, age and height 
were the observed associations with HIV-SN. The association between increasing age and HIV-SN was 
evident in a large US-based cohort study, where the prevalence of HIV-SN increased with age and time 
on ART despite a decline in the use of neurotoxic ART.7 
 
Use of stavudine declined as alternative treatments became available. However, some HIV patients still 
complain of burning and tingling sensations in their legs and arms - likely symptoms of HIV-SN. Here we 
describe the prevalence of HIV-SN in an Indonesian population receiving ART without stavudine. We 
also examined associations with HIV-SN in this setting. The populations served by our clinic are similar 
to 2006, and the HIV-SN assessment methods were identical to the previous study4.  Since 2014, 
healthcare for all Indonesians has been covered by government insurance. With more people aware of 
health issues and seeking treatment, numbers of patients in the clinics have increased.   
Methods 
 
HIV-positive adults who had used ART for at least 12 months but who had never been exposed to 
stavudine were screened for neuropathy at POKDISUS HIV Care Clinic, Cipto Mangunkusumo Hospital, 
Jakarta, Indonesia. Patients with any history of another condition that might be associated with a 
neuropathy, or any condition preventing the patient from being able to provide informed consent were 
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excluded. Neuropathy was assessed using the AIDS Clinical Trials Group Brief Peripheral Neuropathy 
Screen (ACTG-BPNS), and defined as present if the individual had one or more of the lower limb 
neuropathic symptoms (pain, aching or burning, pins and needles or numbness), plus absent ankle 
reflexes or reduced vibration sense at the great toe (vibration of a 128-Hz tuning fork felt for 10 seconds 
or less). We did not diagnose neuropathy in patients with only asymptomatic neuropathic signs, as the 
presence of both symptoms and signs on the ACTG-BPNS tool better associated with impaired 
peripheral nerve function and pathology.8 BPNS and NCS were assessed by a neurologist (FO) and a 
trained general practitioner (DDS).  
 
Patient height and weight were measured during the study assessment. Laboratory, clinical, and 
demographic data were collected from the medical file. Plasma HIV RNA was measured using a Cobas 
Amplicor Monitor (Roche Molecular Diagnostics, Pleasanton, CA). The study was approved by the Ethics 
Committee of the Faculty of Medicine, University of Indonesia (579/UN2.F1/ETIK/2014). All participants 
gave written informed consent. 
 
Statistical analyses were performed using SPSS version 20.0. Demographic, clinical and treatment 
details of patients with and without neuropathy were compared using χ2 tests (dichotomous variables), 
Mann-Whitney tests [non-normally distributed continuous variables, described using median (range)] 
or unpaired t tests (normally distributed continuous variables, described using mean + SD).  
Demographic and clinical details in cohorts surveyed in 2006 and 2016 were also compared using these 
methods. Multivariate analyses of associations with neuropathy in 2016 were performed using multiple 
logistic regression modeling including all factors with p < 0.25 on univariate analyses, followed by a 
stepwise removal process. Odds ratios (OR) and 95% confidence intervals (95% CI) are presented. 
 
Results and Discussion 
 
After screening 2596 patients in 2016, 2399 patients were excluded due to either prior use of stavudine 
(684 patients), <12 months on ART (831 patients), withdrawal from ART (119 patients), diabetes 
mellitus (8 patients), history of stroke (8 patients), schizophrenia (3 patients), vasculitis (22 patients), 
deafness (2 patients), blindness (7 patients), hyperthyroid state (3 patients), systemic lupus 
erythematous (4 patients), cytomegalovirus radiculopathy (1 patient), a history of cancer 
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chemotherapy (6 patients) or refusal to participate (701 patients). 197 patients were tested for 
neuropathy. Demographic and clinical details are described in Table 1.  
 
Twenty-eight patients (14.2%) were assessed as having neuropathy based on the ACTG-BPNS. Most 
were male (71%) and of Malay ethnicity (95%). Lamivudine was used by all patients, and zidovudine 
and nevirapine were used by more than 50% of patients, but choice of antiretroviral regimen was not 
associated with HIV-SN. Over 500 copies HIV RNA/ml and a nadir CD4+ T-cell count below 200 cells/ul 
were associated with HIV-SN on univariate analyses. Whilst one might expect these parameters may 
mark the same people, patients with and without >500 copies HIV RNA/ml had similar nadir CD4 T-cell 
counts (p = 0.31). Before the era of combination ART, HIV-SN was associated with lower CD4 T-cell 
counts and higher plasma HIV RNA.11 When patients receive effective therapy, CD4 T-cell counts 
typically improve and may not register as a risk factor,12 but a lower nadir CD4 T-cell count has been 
described in patients on ART with HIV-SN,13 as observed here. 
 
Neither height, BMI, ethnicity, mode of HIV transmission, ART duration (Table 1), occupation nor 
educational status (not shown) associated with HIV-SN. Age, current CD4 T-cell count, 
isoniazid/pyridoxine therapy (consequent to tuberculosis) 9 and hepatitis C antibody were weakly 
associated with HIV-SN (0.05 < p < 0.10). We also assessed CMV antibodies as CMV is implicated in 
vascular pathology and antibodies may be used as a metric of the burden of CMV.10 However levels of 
CMV antibodies were not associated with HIV-SN. All factors associating even weakly with HIV-SN (p < 
0.2 on univariate analyses; age, nadir <200 CD4 T-cells, current CD4 T-cells, Hepatitis C antibody, HIV 
RNA and Isoniazid/Pyridoxine) were included in logistic regression modeling in a multivariate analysis, 
followed by a stepwise removal procedure.  Carriage of >500 copies HIV RNA/ml [p=0.01, OR 5.2, 95% 
CI (1.5-18)] and increasing age [p=0.06, OR 1.1, 95% CI (0.9-1.1)] independently associated with the HIV-
SN (model p=0.001, pseudo R2=0.06). The association with HIV RNA levels is consistent with data from 
the pre-antiretroviral era11,14 and suggests HIV-SN observed in these patients may have developed 
before ART. 
 
We then compared the data with that obtained in the same clinic when 96 patients receiving stavudine 
were assessed using the ACTG-BPNS in 2006.4 Compared with 2006, in 2016 the proportion of females 
was higher [13.5% in 2006 vs 28.9% in 2016; p = 0.003, OR 2.6, 95%CI (1.3-5)], fewer patients had 
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tuberculosis and received isoniazid/pyridoxine [58.3%  in 2006 vs 45.2% in 2016; p = 0.05, OR 0.6, 95%CI 
(0.4-1)], the patients were older [30.2 + 7.1 years in 2006 vs 35.7 + 5.9 in 2016; p<0.001, mean 
difference 5.4, 95%CI (3.7-7) years] and shorter  [167 + 7.2 cm in 2006 vs 165 + 7.7 cm in 2016; p=0.03, 
mean difference 2.1, 95%CI (0.3-3.9)], fewer patients had nadir counts <200 CD4 T-cells [85% in 2006 
vs 67% in 2016; p = 0.001, OR 0.4, 95%CI (0.2-0.7)], fewer patients had current counts  <200 CD4 T-cells 
[40% in 2006 vs 8.6% in 2016; p<0.001, OR 0.1, 95%CI (0.1-0.3)] and the prevalence of HIV-SN was lower 
[34% in 2006 vs 14.2% in 2016; p<0.001, OR 0.3, 95%CI (0.2-0.6)]. In 2006, age [p=0.04, OR 1.1, 95% CI 
(1-1.1)] and height [p=0.01, OR 1.1, 95% CI (1-1.2)] independently associated with the HIV-SN (model 
p=0.008, pseudo R2= 0.08).   
 
The lower observed prevalence of HIV-SN among HIV patients in our clinic who had never used 
stavudine compared with stavudine-exposed patients in 2006 is striking, as the 2016 cohort was older 
and included more females than the cohort studied in 2006, when female gender associated with 
resistance to HIV-SN. It is therefore likely that lack of stavudine exposure is central to the lower 
neuropathy prevalence observed in the current study. 
 
Fewer patients in the current cohort had been treated for TB, compared with 2006, and the lower rate 
of isoniazid exposure may have impacted neuropathy prevalence. TB patients were prescribed standard 
therapy, including pyridoxine supplementation (25mg/day) throughout isoniazid use. Neuropathy was 
recognized as a side effect of isoniazid in the 1970’s and has been described in 0.2%-10% of patients 
receiving this drug.9 Although use of isoniazid was not associated with HIV-SN in 2006, it was weakly 
associated with HIV-SN in 2016.  However, this was not independent of other observed associations, 
and the lower frequency of isoniazid use in the current cohort is unlikely to explain the lower observed 
HIV-SN prevalence. 
 
Overall we show that HIV-SN remains common, affecting >14% of those treated for HIV in our clinic 
even though patients no longer use stavudine. Increasing age is known risk factor for HIV-SN.5,7 Here 
HIV-SN patients were marginally older that those without neuropathy in both 2006 and 2016. Whilst 
links between HIV-SN and patient age on ART have been attributed to improved life expectancy, 
prolonged exposure to neurotoxic effects of stavudine and other potentially neurotoxic ART 
complicates these analyses1,12.  Here other factors associated with HIV-SN in patients never exposed to 
 6 
stavudine (2016 cohort) mirror associations with neuropathy among HIV patients in the pre-ART era, 
namely HIV replication and low nadir CD4 T-cell count,11 highlighting the need for longitudinal studies 
as patients begin ART. Future work is needed to clarify the degree to which earlier initiation of 
treatment, as recommended by the WHO,15 may prevent the development of HIV-SN.  As even mild 
levels of HIV-SN impair quality of life, work is needed to understand why so many patients are still 
affected, and to inform efforts to prevent HIV-SN. 
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Table 1. Univariate analyses of risk factors for HIV-SN in 2016 and 2006 
 
 2016 
p 
2006 
p  SN free  
(n=169) 
SN 
(n=28) 
SN free 
(n=64) 
SN 
(n=32) 
Female gendera 28% 32% 0.66 19% 3% 0.03 
Age, yearsb 35.3 + 5.8 37.6 + 6.5 0.06 29.4 + 6.7 32 + 7.6 0.12 
Height, cmb 165 + 8 165 + 6 0.81 166 + 7 170 + 8 0.02 
BMIb 22.2 + 3.3 22.8 + 3.7 0.39 20.7 + 2.9 21.3 + 2.7 0.17 
Malay ethnicity 95% 91% 0.84 70% 58% 0.65 
IVDU riska 56% 54% 0.44 73% 67% 0.54 
Hepatitis C antibodya 33% 50% 0.06 48% 58% 0.35 
Isoniazid/Pyridoxinea 43% 60% 0.06 52% 64% 0.29 
>500 copies HIV RNA /ml a 4% 18% 0.02 Not done Not done  
Nadir <200 CD4 T-cells/ula 65% 82% 0.05 86% 96% 0.43 
Nadir CD4 T-cells/ul 122 (103-729) 65 (11-428) 0.25 53 (2-633) 33 (1-466) 0.2 
Current <200 CD4 T-cells/ula 8% 14% 0.2 32% 56% 0.02 
Current CD4 T-cells/ul 447 (21-1166) 397 (103-729) 0.08 265 (11-1014) 187 (33-639) 0.11 
CMV antibody (AUx10-3) 27.7(0.52-365) 27.3(3.8-182) 0.7 Not done Not done  
ART 
Stavudine 0 0  100% 100%  
Lamivudine 100% 100%  98% 100% 0.67 
Zidovudine 85% 93% 0.20 60% 40% 0.82 
Nevirapine 70% 79% 0.24 89% 61% 0.78 
Efavirenz 47% 40% 0.29 49% 40% 0.65 
Tenofovir 34% 36% 0.50 0 0  
Lopinavir/ Ritonavir 12% 14% 0.49 16% 10% 0.51 
Emtricitabine 9% 7% 0.55 0 0  
ART duration, yearsc 4.1 (1 – 12.7) 5.4 (1 – 10.9) 0.33 1.3 (0.2-3.5) 1.2(0.1-3.3) 0.36 
 
a categorical data assessed with Fischer’s exact tests,  
b mean + standard deviation, assessed with Student’s t tests (parametric data) 
c median (range), assessed with Mann-Whitney tests (non-parametric data) 
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